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Abstract
Asbestosis is diagnosed with a combination of historical, clinical and
radiological findings in the absence of another cause. Histology is required
when uncertainty exists, with lung biopsy via VATs being gold standard.
Transbronchial cryobiopsy is becoming increasingly popular for diagnos-
ing interstitial lung disease and may provide sufficient lung sample to
demonstrate asbestosis. A 73 year old man presented with dyspnoea on a
background of rheumatoid arthritis, previous methotrexate use and asbes-
tos exposure. Examination revealed fine crackles in the mid and lower
zones bilaterally without signs of pulmonary hypertension. The presence
of pleural plaques and basal interstitial reticulation on HRCT was sugges-
tive of asbestosis but histology was required to differentiate this from
rheumatoid or methotrexate associated ILD. Samples of lung tissue were
obtained via transbronchial cryobiopsy, demonstrating fibrosis and asbes-
tos fibres consistent with asbestosis. Transbronchial cryobiopsy appears
effective in obtaining sufficient parenchymal lung samples to diagnose
asbestosis when clinical uncertainty exists.
Introduction
Asbestosis is a diffuse pulmonary fibrosis resulting from
the excessive inhalation of asbestos fibres [1]. It is a slow
progressing disease that has a lead time of 15–40 years
from exposure until onset of symptoms [2–4]. Diagnosis is
usually made on probability based on a history of asbestos
exposure, clinical features of pulmonary fibrosis, absence of
another cause of fibrosis, and radiological findings. Often,
histological confirmation is required, such as when atypical
clinical or radiological features are present or for medicole-
gal reasons associated with compensation. Due to insuffi-
cient tissue samples obtained via traditional bronchoscopic
transbronchial biopsy, current recommendations suggest
biopsy via video-assisted thoracoscopic surgery [5]. Trans-
bronchial cryobiopsy is an increasingly popular technique
for the diagnosis of interstitial lung disease and may pro-
vide lung samples of sufficient size for the diagnosis of
asbestosis.
Case Report
A 73-year-old former smoker (5 pack-years) presented for
respiratory evaluation with progressive exertional dyspnoea
over the course of a few years. He described heavy
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occupational asbestos exposure between 18 and 55 years of
age while employed on ships removing asbestos lagging
from insulated pipes, rarely using protective ventilatory
apparatus. Relevant medical background included rheuma-
toid arthritis previously on methotrexate, type 2 diabetes
mellitus, hypertension, and obesity.
On examination, he was noted to be morbidly obese
(body mass index 40.2), saturating 96% on room air with a
respiratory rate of 24/min, and was normotensive. There
was no clubbing or lymphadenopathy. Fine crackles were
auscultated in the mid and lower zones bilaterally. Cardiac
examination was normal, and there were no clinical fea-
tures of pulmonary hypertension.
Pulmonary function tests demonstrated a forced expira-
tory volume in 1 second (FEV1) of 2.09 L (82.4% predicted),
forced vital capacity (FVC) of 2.75 L (82.7% predicted) with
FEV1/FVC ratio of 0.76, Total Lung Capacity (TLC) of 4.46
(72.2% predicted), and Diffusing capacity of the lungs for
carbon monoxide (DLCO) of 12.95 (57.1% predicted),
demonstrating a parenchymal restrictive process.
A high-resolution computed tomography chest showed
calcified pleural plaques bilaterally, predominantly in the
lower zones. Increased subpleural reticular markings at the
lung bases were present, with relative sparing of upper
zones. There was no obvious honeycombing (Fig. 1).
A diagnosis of asbestosis was suspected clinically, but dif-
ferential diagnoses included idiopathic pulmonary fibrosis,
rheumatoid arthritis, and methotrexate-associated interstitial
lung disease. The presence of pleural plaques, whilst con-
firming asbestos exposure, was insufficient for the confirma-
tion of asbestosis. Due to the importance of differentiating
these causes, histological confirmation was sought.
The patient underwent elective rigid bronchoscopy
under general anaesthesia. The central airways appeared
macroscopically normal without significant endoluminal
abnormality. Bronchoalveolar lavage was performed from
the right middle lobe and from the lingula, both yielding a
clear, watery return. Under fluoroscopic guidance, a
1.9-mm cryoprobe was inserted into the right lower lobe
basal segments (RB8, RB9 and RB10) and the lateral seg-
ment of the right middle lobe (RB4). The procedure was
uncomplicated, and no pneumothorax was noted on post-
procedure chest X-ray.
The bronchoalveolar lavage demonstrated bronchial
cells and macrophages amidst a moderate number of neu-
trophils. An isolated ferruginous body was present.
Two tissue biopsies (4 mm and 6 mm across) from the
right middle lobe showed alveolated lung parenchyma with
mild peribronchiolar fibrosis associated with some mild
type 2 pneumocyte hyperplasia. Multiple asbestos bodies
were seen, with a count of at least 14 per cm2 (Fig. 2).
A further four biopsies (ranging 4–7 mm across) from
the right lower lobe comprised a higher proportion of
bronchial wall with cartilage and peribronchial glands as
well as alveolated lung parenchyma. There were also asbes-
tos bodies present (at least 9 per cm2).
Of relevance, no significant interstitial inflammatory
infiltrates/lymphoid aggregates, granulomas, vasculitis, hae-
morrhage, or other specific features were noted to suggest a
connective tissue disease as the underlying pathology.
On the basis of this histopathology and the clinical and
radiological information, a diagnosis of asbestosis was made.
Discussion
This case demonstrates the utility of transbronchial lung
cryobiopsy in confirming the aetiology of asbestos-related
interstitial lung disease in the presence of diagnostic uncer-
tainty. The cryobiopsy technique allows for a larger
Figure 1. Axial (A) and coronal (B) high-resolution computed tomography chest views demonstrating mild subpleural reticulation. Mediastinal win-
dow (C) demonstrates diaphragmatic calcification (arrows).
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specimen yield, increasing the probability of sampling
pathological tissue compared with conventional transbron-
chial biopsy [6–8].
The gold standard for diagnosis of asbestosis is made
based on the presence of diffuse interstitial pulmonary
fibrosis in a subpleural distribution together with the histo-
logical finding of asbestos bodies implanted in the air
spaces or within regions of fibrosis. On light microscopy,
the asbestos bodies appear beaded or dumbbell-shaped
and can be recognized by their thin, transparent core.
They form as a result of the iron-protein-
mucopolysaccharide coating of asbestos fibres. Guidelines
state that two or more asbestos bodies per square centi-
metre of a 5 μm thick lung section are required to make
the diagnosis [1]. Due to variability in fibre counts within
smaller transbronchial specimens, it is currently suggested
that optimal samples for analysis should comprise 2 cm3
blocks from three anatomical sites (usually from the apical
upper, apical lower and basal segments of the lung) [1].
Asbestos bodies can be formed by other substances,
for example, cellulose. Electron microscopy (EM) can be
used to determine if asbestos bodies contain asbestos
fibres and can also determine fibre type. EM was not
performed in this case, but the history of significant
asbestos exposure and the finding of asbestos bodies in
high numbers is likely to indicate significant asbestos
exposure.
In cases of interstitial lung disease (ILD) where there is
diagnostic uncertainty and a lung biopsy is required, surgi-
cal lung biopsy is the gold standard for tissue sampling as
Figure 2. (A) and (B) Examples of ferruginous bodies found in the cryobiopsies of alveolar lung parenchyma from this patient. Arrows indicate the
characteristic pigmented beaded bodies in the interalveolar septae. (C) Low-power view of Haematoxylin and eosin (HE) stain containing alveolar
parenchyma. (D) Perls’ stain highlighting asbestos body.
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bronchoscopic transbronchial biopsies using forceps pro-
vides too little parenchymal tissue [8]. However, surgically
acquired biopsies are associated with higher morbidity and
mortality when compared with bronchoscopy. Comorbid-
ities that are often associated with ILD, such as pulmonary
hypertension and hypercapnia, compound this risk and
can often preclude patients from being surgical candidates.
In interstitial lung diseases, transbronchial lung cryo-
biopsy has been shown to improve the diagnostic yield
when compared with conventional transbronchial biopsies
(obtained via forceps), providing larger specimen size
(often measure 0.5 cm or more in greatest diameter) with-
out associated crush artefacts [9]. No studies to date have
directly compared the diagnostic accuracy of transbron-
chial cryobiopsy with that of surgical lung biopsies. How-
ever, several studies demonstrate the safety and efficacy of
transbronchial biopsies in the setting of diffuse parenchy-
mal lung diseases, with lower rates of complications such
as bleeding, shorter hospital stays, and improved mortal-
ity [6,7,9].
Current guidelines make recommendations for the diag-
nosis of asbestosis based on surgical biopsy sample sizes
[1]. However, these do not reflect the increasingly available
and potentially safer method of transbronchial cryobiopsy,
which, as our case has demonstrated, can also provide
large-enough lung samples to demonstrate asbestos bodies
in sufficient numbers to be helpful in attributing the cause
of pulmonary fibrosis. Further studies directly comparing
the diagnostic efficacy and safety profiles between these
two methods in the setting of asbestosis are needed.
To our knowledge, this is the first description of the
transbronchial cryobiopsy technique to confirm a diagno-
sis of asbestosis. Bondue and colleagues noted the presence
of asbestos fibres in a cryobiopsy specimen from a patient
with a radiological pattern of Usual interstitial pneumonia
(UIP) but the low fibre count dissuaded the pathologists
from attributing the fibrosis to asbestos [8].
In conclusion, this case demonstrates the effectiveness
of transbronchial cryobiopsy as a modality for obtaining
lung parenchymal samples of adequate size to demonstrate
asbestos bodies in sufficient numbers to confirm
significant asbestos exposure and to indicate asbestos
exposure as the cause of pulmonary fibrosis. Current
guidelines could be modified to reflect advances in biopsy
techniques.
Disclosure Statement
Appropriate written informed consent was obtained for
publication of this case report and accompanying images.
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